Skip to main content
BBIO
NASDAQ Life Sciences

KKR Sells 5M BridgeBio Shares at $77.42, Exits 5% Ownership

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$80
Mkt Cap
$15.617B
52W Low
$46.81
52W High
$93.415
52W Position info
71% above low
Off High info
14% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

BBIO sits 71% above its 52-week low of $46.81.

Summary

KKR sold 5 million BridgeBio shares at $77.415 each, cutting its stake to 4.7% and exiting 5% ownership. The sale closed August 17, 2026, with a 30-day lock-up on further sales.


Key Events · Ownership and Investor Activity · BBIO

  • KKR Sells 5M Shares

    KKR Genetic Disorder L.P. sold 5,000,000 shares at $77.415 per share in an underwritten offering, generating approximately $387 million in gross proceeds.

  • Ownership Falls Below 5%

    After the sale, KKR's aggregate beneficial ownership is 9,232,739 shares (4.7%), crossing below the 5% threshold and triggering this exit filing.

  • 30-Day Lock-Up

    KKR agreed to a 30-day lock-up restricting further sales or hedging of BridgeBio shares, subject to certain exceptions.

  • Preferred Stock Purchase

    An Alternative Vehicle managed by KKR purchased 133,900 shares of Series A Preferred Stock for $1,000 per share on July 1, 2026, convertible into 971,768 common shares.


Analysis · BBIO · Life Sciences

A major long-term investor, KKR Genetic Disorder L.P., sold 5 million shares of BridgeBio Pharma in an underwritten offering at $77.415 per share, generating approximately $387 million in gross proceeds. The sale closed on August 17, 2026, and reduced KKR's aggregate beneficial ownership to 9,232,739 shares, or 4.7% of the company, crossing below the 5% reporting threshold. This is a significant distribution by a sophisticated institutional holder, and the exit filing signals a reduced commitment to the stock. The offering was priced at a modest discount to the current market price of $80.00, and KKR has agreed to a 30-day lock-up, limiting near-term additional sales. The transaction follows a period of strong clinical and regulatory progress for BridgeBio, including FDA priority review for BBP-418 and a $1 billion convertible preferred financing in July 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BBIO was trading at $80.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.6B. The 52-week trading range was $46.81 to $93.42. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BBIO - Latest Insights

BBIO
Oct 29, 2026, 4:52 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.69
Real-time Price: $76.03 info
Change: +$5.34 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $71.44
Real-time Price: $76.03 info
Change: +$4.59 (+6%) info
Market Cap: $14.811B info
BBIO
Oct 29, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $70.67
Real-time Price: $76.03 info
Change: +$5.36 (+8%) info
Market Cap: $14.811B info
BBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $65.75
Real-time Price: $76.03 info
Change: +$10.28 (+16%) info
Market Cap: $14.811B info
BBIO
Oct 11, 2026, 2:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $65.35
Real-time Price: $76.03 info
Change: +$10.68 (+16%) info
Market Cap: $14.811B info